

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Overview And Statistic For 2024-2033

The Business Research Company's Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024 – Market Size, Trends, And Market Forecast 2024-2033

LONDON, GREATER LONDON, UK, June 24, 2024 /EINPresswire.com/ -- The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market, which targets certain types of breast cancer, is



experiencing significant growth, driven by advancements in targeted therapy. The market is projected to grow from \$10.18 billion in 2023 to \$25.17 billion in 2028, representing a compound annual growth rate (CAGR) of 19.5%. This growth is fueled by various factors, including increasing investment in research and development for breast cancer treatment, expanding indications, and emerging pipeline molecules.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs"
The Business Research
Company

Rising Demand for Freshwater Drives Market Growth
The rising demand for freshwater is a significant factor
contributing to the growth of the axial flow pump market,
facilitating the movement of large water volumes for
various applications. A Guardian report forecasts a 40%
shortfall in freshwater supply by 2030, emphasizing the

need for effective water management solutions.

Explore the global axial flow pump market with a detailed sample report: https://www.thebusinessresearchcompany.com/sample-request?id=13121&type=smp

Key Players and Market Trends

Key players such as Pfizer Inc., Merck & Co. Inc., and Novartis AG are focusing on product innovation to enhance the effectiveness of CDK 4/6 inhibitor drugs. For example, Eli Lilly and Company received approval for Verzenio (abemaciclib) as the first and only CDK4/6 inhibitor in

combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer.

Segments

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market covered in this report is segmented –

- 1) By Drug Type: Palbociclib (Ibrance), Ribociclib (Kisqali), Abermaciclib (Verzenio)
- 3) By Patient: Pre-Menopausal, Post-Menopausal, Other Patients
- 3) By End-Users: Hospitals, Clinics, Research Laboratories, Retail Pharmacies

Geographical Insights: North America Leading the Market

North America was the largest region in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market in 2023, with significant contributions from the United States and Canada. The region's leadership is attributed to advanced healthcare infrastructure, high R&D investments, and increasing prevalence of breast cancer.

Access the complete report for in-depth analysis:

https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

<u>Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market</u> Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market size, cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market drivers and trends, cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market major players, competitors' revenues, market positioning, and market growth across geographies. The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By <u>The Business Research Company:</u>
Narcotic Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Antiglaucoma Drugs Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/722343428

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.